Hovels, A.M.

cancer breast cancer study breast analysis therapy tamoxifen outcome analyses treatment effect patient cost-effectiveness difference health carryover effect recurrence evaluation adjuvant trial model sensitivity horizon carryover exemestane postmenopausal women adjuvant therapy characteristic time horizon 5 years letrozole hazard ratio modeling women early-stage breast cancer article method event review survival modeling methods sensitivity analyses pharmacoeconomic value intervention perspective speci receptor health-care payer perspective sensitivity analysis age breast cancer res postmenopausal estrogen assessment quality result canada interest publication sensitivity analysis comparison justi fied author estrogen receptor –positive table probability anastrazole lifetime country adjuvant treatment impact anastrozole subtype hazard ratio health-care health states cycle length state aromatase inhibitors